BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced memorandum of understanding with the Canadian government to produce NVX-CoV2373, the Company’s protein-based vaccine candidate against COVID-19 in Canada.

Maryland is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

Texas is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

New York is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

McGinley Orthopedics, the developer of the patented Lever Action Plate System®, partnered with hand surgeons at Shriners Hospitals for Children - Philadelphia to implant the first plate this week

To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers® in collaboration with University of Colorado, and Miami University were recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).

Previous predications in pharmaceutical transportation trends, highlighting declining air passenger numbers and air freight demand increasing, have been pandemic propelled.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming to innovate in the complex field of neurological diseases. The incubator space is located at the Eisai Center for Genetics Guided Dementia Discovery (G2D2) facility and will become part of BioLabs’ national biotechnology network

Adamis Pharmaceuticals Corporation, announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $1.11 per share.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the closing of its previously announced underwritten public offering of 35,000,000 shares of common stock of the Company at a price to the public of $1.00 per share.